Cancer Cell
. 2021 Jan 5;S1535-6108(21)00001-5.
doi: 10.1016/j.ccell.2021.01.001. Online ahead of print.
Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients
Sultan Abdul-Jawad 1 , Luca Ba? 2 , Thanussuyah Alaguthurai 3 , Irene Del Molino Del Barrio 4 , Adam G Laing 5 , Thomas S Hayday 5 , Leticia Monin 6 , Miguel Mu?oz-Ruiz 6 , Louisa McDonald 7 , Isaac Francos Quijorna 8 , Duncan McKenzie 6 , Richard Davis 5 , Anna Lorenc 5 , Julie Nuo En Chan 1 , Sarah Ryan 9 , Eva Bugallo-Blanco 1 , Rozalyn Yorke 9 , Shraddha Kamdar 5 , Matthew Fish 10 , Iva Zlatareva 5 , Pierre Vantourout 5 , Aislinn Jennings 10 , Sarah Gee 5 , Katie Doores 11 , Katharine Bailey 12 , Sophie Hazell 12 , Julien De Naurois 13 , Charlotte Moss 14 , Beth Russell 14 , Aadil A Khan 15 , Mark Rowley 16 , Reuben Benjamin 17 , Deborah Enting 14 , Doraid Alrifai 13 , Yin Wu 18 , You Zhou 19 , Paul Barber 1 , Tony Ng 1 , James Spicer 1 , Mieke Van Hemelrijck 14 , Mayur Kumar 20 , Jennifer Vidler 21 , Yadanar Lwin 21 , Paul Fields 22 , Sophia N Karagiannis 23 , Anthony C C Coolen 24 , Anne Rigg 13 , Sophie Papa 25 , Adrian C Hayday 26 , Piers E M Patten 27 , Sheeba Irshad 28
Affiliations
- PMID: 33476581
- DOI: 10.1016/j.ccell.2021.01.001
Abstract
Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.
Keywords: COVID-19; SARS-CoV-2; antibodies; cancer; hemato-oncological; immune; seroconversion; vaccine; virus shedding.